Hyperactivation of the insulin-like growth factor receptor I signaling pathway Is an essential event for cisplatin resistance of ovarian cancer cells

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2996-3003

  Eckstein, Niels ^a   Servan, Kati ^a   Hildebrandt, Barbara ^b   Pölitz, Anne ^b   Von Jonquières, Georg ^a   Wolf Kümmeth, Sybille ^a   Napierski, Inge ^a   Hamacher, Alexandra ^a,b   Kassack, Matthias U ^b   Budczies, Jan ^c   Beier, Manfred ^b   DieteL, Manfred ^c   Royer Pokora, Brigitte ^b   Denkert, Carsten ^c   Royer, Hans Dieter ^a  

^a CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; BIOSYNTHESIS; CHROMOSOME ABERRATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETICS; METABOLISM; OVARY TUMOR; SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INSULIN-LIKE GROWTH FACTOR I; OVARIAN NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 66149092327     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3153     Document Type: Article

References (50)

1. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5: 9-24.
2. Aábo K, Adams M, Adnitt P, et al.; Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78:1479-1487
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-2529
4. Wang D, Lippard SJ. Cellular processing of platinum, anticancer drugs. Nat Rev Drug Discov 2005;4: 307-320
5. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
6. Markman M. The promise and perils of 'targeted therapy, of advanced ovarian cancer. Oncology 2008;74< 1-6.
7. Eckstein. N, Servan K, Girard L, et al. Epidermal, growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol. Chem 2008;283:739-750
8. Eva A, Robbins KC, Andersen PR, et al. CeËular genes analogous to retroviral one genes are transcribed in. human tumour cells. Nature 1982;295:116-119
9. Behrens BC, Hamilton TC, Masada H, et al. Charac- terization of a cis-dlamminedichloroplatin.um(II)-resis- tant human ovarian cancer cell line and its use in evaluation of platinum, analogues. Cancer Res I987;47: 414-418
10. Brown R, Clugston C, Burns P, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-684
11. Holford J, Rogers P, Kelland LR. ras mutation and platinum, resistance in. human ovarian, carcinomas in vitro. Int J Cancer 1998;77:94-100.
12. Mitelman F, editor. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995.
13. Trost D, Hildebrandt B, Beier M, Müller N, Germing U, Royer-Pokora B. Molecular cytogenetic profiling of complex karyotypes In primary myelodysplastlc syn- dromes and acute myeloid leukemia. Cancer Genet Cytogenet 2006;165:51-63.
14. Knight SJ, Lese CM, Precht KS, et al. An optimized set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 2000:67: 320-332
15. Evers C, Beier M, Poelitz A, et al. Molecular definition, of chromosome arm 5q deletion end points and detection, of hidden aberrations in patients with myelodysplastlc syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Can- cer 2007;46:1119-1128
16. Hupe P1 Stránský N1 Thiery JP1 Radvanyi F1 Barlllot E. Analysis of array CGH data: from signal, ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-3422
17. Pollak MN, Schernhammer ES, Hanklnson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518
18. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated, by stress and inflammation. Physiol Rev 2001;81:807-869
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101
20. Durai R, Davies M, Yang W, et al. Biology of insulin- like growth factor binding protein-4 and its role in. cancer [review]. Int J Oncol 2006;28:1317-1325
21. Schilder RJ, Hall L, Monks A, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian, cancer. Int J Cancer 1990;15:416-422
22. Petru E, Sevin BU, Perros J, et al. Comparative chemosensitivity profiles in four human ovarian carci- noma cell lines measuring ATP bioluminiscence. Gynecol Oncol 1990;38:155-160
23. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-3676
24. Geisinger KR, Kute TE, Pettenatl MJ, et al. Charac- terization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989;63: 280-288
25. Baldwin WS, Curtis SW Cauthen CA, Risinger JI, Korach KS, Barrett JC. BG-I ovarian, cell line: an alternative model for examining estrogen-dependent growth in vitro. In vitro Cell Dev Biol Anim 1998:34: 649-654
26. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525
27. Sawyers CL. The cancer blomarker problem. Nature 2008:452:548-552
28. Prasad M, Bernardini M, Tsalenko A, et al. High definition cytogenetics and oligonucleotide aCGH anal- yses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 2008;47:427-436
29. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-288
30. Kuroda H, Mandai M, Konishi I, et al. Human chorionic gonadotropin (hCG) inhibits cisplatin-in- duced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer 1998;76:571-578
31. Poretsky L, Cataldo NA, Rosenwoks Z, Giudice LC. The insulin-related ovarian regulatory system in. health and disease. Endocr Rev 1999;20:535-582
32. KaIH KR, Conover CA. The Insulin-like growth factor/ insulin, system in epithelial ovarian, cancer. Front Blosci 2003;8:d714-22.
33. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-5389
34. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and Its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993;69:756-760
35. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63:1311-1316
36. Gotlieb WH, Bruchim I, Gu. J, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2005;100:389-396
37. Burke F, ReIf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996:8: 578-585
38. Berns EM, Klijn JG, Henzen-Logmans SC, et al. Receptors for hormones and growth factors and (onco)- gene amplification in human, ovarian cancer. Int J Cancer 1992;52:218-224
39. van Dam PA, Vergüte IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor, and epidermal growth factor receptor in ovarian, carcinoma. J Clin Pathol 1994(47: 91.4-9
40. Karasik A, Menczer J, Pariente C, Kanety H. Insulin- like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin. Endocrinol Metabol 1994;78:271-276
41. Na Y, Kim KT, Yoo JB, Moon H, Hwang YY, Shin JH. Significance of Insulin-likegrowth factor-]. (IGF-I) in the ascites of ovarian, cancer. Korean J Gynecol Oncol Colposc 1995;6:227-234
42. Spentzos D, Cannlstra SA, Grail F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 2007;14: 781-790
43. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007;25:346-354
44. Shayesteh L, Lu Y, Kuo WI., et al. PI.K3CA Is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
45. Levine DA, Bogom.oln.iy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian, and breast cancers. Clin Cancer Res 2005;11:2875-2878
46. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-285
47. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. A.KT2 inhibition of cisplatin- induced JNK/p38 and Bax. activation by phosphorylation of ASKl: implication of AKT2 in chemoresistance. J Biol Chem 2003;278:23432-23440
48. Weroha SJ, Haluška P. IGF-I receptor inhibitors in clinical, trials - early lessons. J Mammary Gland Biol Neoplasia 2008:13:471-483
49. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinosltide 3-kinase - moving towards therapy. Biochim Biophys Acta 2008;1784:159-185
50. Mabuchi S, Altomare DA, Cheung M, et al. RADOOI inhibits human ovarian cancer cell proliferation, enhan- ces cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res 2007; 13: 4261-4270